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the cervix, allowing lower doses of misoprostol to induce expulsion of the dead fetus. It shortens the induction-delivery interval. [5] [6] [7] Majority of the previous studies on the induction of labor in women with IUFD (varied gestational age between 20 and 42 weeks) were observational studies with only a few randomized controlled trials, that too with small sample sizes. The doses of misoprostol and the route of administration also varied widely. [5] [6] [7] [8] [9] [10] [11] Hence, we conducted a randomized placebo-controlled trial to compare the effi cacy and safety of mifepristone plus misoprostol versus oral misoprostol alone for induction of labor in IUFD.
PATIENTS AND METHODS
This clinical trial was conducted at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India from November 2011 to September 2013. The study protocol was approved by the Institute Ethics Committee (Human studies) at JIPMER (No. SEC/2011/4/81). Patients diagnosed to have IUFD after 28 weeks of gestation (considered viable in developing and underdeveloped countries) were assessed for eligibility. Women with IUFD in a singleton pregnancy who were not in labor and had intact membranes were eligible to participate in the trial. Women with IUFD and chorioamnionitis, previous uterine surgery, placenta previa or unexplained vaginal bleeding, allergy to mifepristone and misoprostol, adrenal insuffi ciency, severe asthma, porphyria, major degree cephalopelvic disproportion, or hypertensive disorders of pregnancy were excluded from the trial.
Informed written consent was obtained from all participants. After thorough initial clinical assessment for eligibility, routine investigations and other necessary investigations were done as needed. Consenting women were randomly assigned to receive any of the two regimens. Block randomization with varying block size generated by a computer was used to randomize patients to the study arms. In one group, women received 200 mg oral mifepristone followed by 50 μg oral misoprostol every 4 h up to a maximum of 5 doses. In the other group, women received oral placebo (Tab. Calcium 250 mg) followed by 50 μg oral misoprostol every 4 h up to a maximum of 5 doses. The interval between mifepristone/placebo and the fi rst dose of misoprostol was 24 h. After misoprostol administration, maternal pulse, blood pressure, temperature, uterine contractions, and systemic symptoms were monitored 4 th hourly during the fi rst stage and every 30 min during the second stage. Successful treatment was defi ned as delivery within 72 h of the fi rst misoprostol dose. In case of failure of induction, other procedures such as extra-amniotic carboprost (PGF2α) or ethacridine lactate instillation, vaginal or sublingual PGE1, and oxytocin augmentation were used at the discretion of the treating unit consultant's decision.
Women were followed up to hospital discharge, which was usually 24-48 h after the delivery. Adverse effects of the drugs such as nausea, vomiting, diarrhea, and fever, and complications of delivery such as hemorrhage and trauma were noted during intrapartum and postpartum periods. Completeness of uterine evacuation was confi rmed by examination of expelled products of conception or by ultrasonogram in select cases when warranted clinically. The primary outcome measure was the induction to delivery interval. Other methods used in case of induction failure, adverse effects of drugs, complications of delivery, and complete uterine evacuation were the secondary outcome measures.
Sample size
Sample size was estimated assuming an expected difference of 10 h in the mean induction to delivery time between the two groups with a standard deviation (SD) of 15 h, at 5% level of signifi cance and 80% power. The estimated sample size was 36 participants in each group.
Statistical analysis
We used the SPSS 19 for Windows statistical package (SPSS Inc., Chicago, Illinois, USA) for data analysis. Normally distributed continuous variables were summarized as mean ± SD and compared using independent t-test. Induction to delivery interval was not normally distributed. Hence, it was summarized as median (interquartile range) and compared using Wilcoxon rank-sum test. The number of treatment failure was compared by Fisher's exact test. All tests were two-sided and P < 0.05 was considered statistically signifi cant.
RESULTS
During the study, 72 women with IUFD were recruited, and all of them were followed up to hospital discharge [ Figure 1 ]. The groups were similar with respect to maternal age, gravidity, parity, body-mass index, gestational age, and fundal height. There were no signifi cant differences in the mean initial Bishop score, duration of loss of fetal movements, and birth weight of the baby [ Table 1 ].
Age of study participants ranged from 18 to 36 years. Out of 72 participants, four were teenage pregnancies (1 in mifepristone group, 3 in the placebo/only misoprostol group) and three Women admitted with IUFD were assessed for eligibility Enrollment Figure 1 : CONSORT flow diagram women were elderly gravidae (1 in mifepristone group, 2 in the placebo group). The majority of women were in the age group of 20-24 years and most participants (40 [56%] women) were primigravidae -21 (58%) women in mifepristone and 19 (53%) women in the placebo group.
Distribution of gestational age, mean fundal height, distribution of Bishop Score, and duration of loss of fetal movements were similar in both the groups. Majority of the patients in both the groups (>80%) presented within 5 days of loss of fetal movements. Mean birth weight was little higher in combination group but was not statistically significant with [ Table 1 ]; (P = 0.164).
Median time to delivery following induction was 14.3 h and 16.4 h in the combination group and misoprostol group, respectively. The difference, however, was not statistically significant (P = 0.437); [ Table 2 ]. A number of misoprostol doses required were also similar in the two groups (P = 0.465); [ Table 2 ]. One woman in misoprostol alone group did not expel the products of conception completely. Instrumental evacuation was done for her. Three patients delivered with mifepristone alone in the combination group. However, in misoprostol group, no delivery happened before misoprostol administration. This difference was not statistically significant. 
dIScuSSIon
In this trial, both regimens were well tolerated, and it appears that the combination regimen is marginally more efficacious with shorter induction to delivery times and comparatively fewer failures. However, the differences were not statistically significant.
In an observational study after 24 weeks of gestation with 200 mg oral mifepristone and 200/100 mcg of vaginal misoprostol, Wagaarachchi et al. concluded that combination method was safe and effective when compared to either of the drugs used alone. [5] In 2005, Fairley et al. reported that after 24 weeks of gestation while combination (oral mifepristone 200 mg plus vaginal misoprostol 400 micrograms up to four doses) regimen was effective, oral misoprostol administration had a higher incidence of gastrointestinal side effects. [7] In 2006, Ranganath and Shankaregowda (Unpublished data) performed an observational study after 24 weeks of gestation with dosages similar to Wagaarachchi et al. and concluded that combination of mifepristone and misoprostol regimen was more effective and safe to induce labor in late IUFD with fewer side effects and need for less intense monitoring. [8] In 2007, Väyrynen et al. in their study from 21 to 42 weeks of gestation found similar safety and efficacy for the combination (200 mg of oral mifepristone followed by a low dose 25 mcg of vaginal misoprostol) and 100 mcg vaginal misoprostol only group. However, pretreatment with mifepristone reduced the induction to delivery interval. [9] Sharma et al. found that combination of 200 mg of oral mifepristone and 100/50 mcg (<37 weeks/more than 37 weeks, respectively) misoprostol was more effective than the same dose of misoprostol given alone in women with IUFD after 28 weeks, and the number of doses required was less in the combination group. [10] In 2013, Praveena et al. found in a randomized trial (20-42 weeks of gestation) that the combination of 200 mcg oral mifepristone and 200/50 mcg vaginal misoprostol in intermediate and late IUFD, had a shorter induction to delivery interval and a lesser requirement for misoprostol doses when compared to misoprostol only group. [11] In the present study, mean induction-delivery interval in both the groups was higher when compared to other studies. This might be due to the lower dose of misoprostol (50 µg) used for all gestational ages more than 28 weeks. The interval between administrations of mifepristone to misoprostol was 24 h in our trial, which is less compared to the majority of the other studies. However, with this low-dose misoprostol regimen was well tolerated, and there were no adverse effects noted in both groups.
The strengths of the present study are -this was a randomized placebo-controlled trial; there were no dropouts; and we evaluated a lower dose of oral misoprostol to minimize the adverse effects. The cervical status (Bishop Score) was not reassessed 24 h after intake of mifepristone/placebo in this trial. This could be a limitation. This would help to assess the action of mifepristone on the cervix. A larger sample size is required to study better the complications and adverse effects.
concluSIonS
Addition of mifepristone to appears to be more effective than misoprostol alone for induction of labor in intermediate and late IUFD, although the differences were not statistically significant. A larger clinical trial is needed to define the management of IUFD.
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